Remora Biotech
Michael R. Bavand is a highly experienced professional in the fields of biotechnology and pharmaceutical development, currently serving as a Member of the Board of Directors at Glycocalyx Therapeutics AG and Co-Founder & Chief Technology Officer at Cellula Therapeutics SA. With a robust background as an Entrepreneur & CTO at Remora Biotech, Bavand has been instrumental in translating scientific innovations into therapies across immunology and oncology. Previous roles include President & CEO of ChromaCon, Director of Technology & Operations at Kuros Biosciences, and Founder of Siegfried Biologics. Academic credentials include a Dr. sci.nat. in Biochemistry from ETH Zürich and Executive Education from Stanford University Graduate School of Business and Harvard Business School.
This person is not in any teams
Remora Biotech
Immunotherapy has an immense and growing impact on medicine and society : vaccines against pandemics, monoclonal antibodies – the most successful class of drugs, breakthrough cures of cancer and autoimmune diseases, and new hopes to fight degenerative diseases. As immunologists and serial entrepreneurs, we contributed, at our small individual scale, to this biopharmaceutical revolution driven by immunology. We now join forces at Remora Biotech to leverage our entrepreneurial experience and, thanks to our supporting investors, to scale-up our ability to nurture and develop innovative life-changing immunotherapies. With our growing team and network of academic partners, business-oriented scientists, patent experts, drug developers and finance professionals, we create, finance, and manage a portfolio of daughter companies from discovery to clinical proof-of-concept. We aim at maximizing their odds of success and their strategic value for pharma partners while keeping capital efficient. Investors keen to gain exposure to this high-growth and high-impact sector, under the leadership of seasoned entrepreneurs, may become a shareholder of Remora Biotech and co-invest in our daughter companies.